Dr. Weeks’ Comment: Soy milk helps and Halean 951 helps more .
Effects of Commercially Available Soy Products on PSA in Androgen-deprivation-naïve and Castration-resistant Prostate Cancer
Objective: No standard therapeutic option exists for men with prostate cancer who have failed local therapy, have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. Soy products are able to affect PSA kinetics in some men with prostate cancer, and this effect has been attributed to the decreased expression of the androgen receptor and other mechanisms.
Methods: We treated 10 men with rising PSA levels after radical prostatectomy and salvage radiotherapy with commercially available soy products. Scans revealed no gross metastatic disease. Three men also had been receiving androgen-deprivation therapy (ADT) and had rising PSA levels that were consistent with castration-resistant (CR) disease. We reported the results of this modality on PSA levels, PSA kinetics, and the duration of PSA response.
Results: Responses occurred in 4 of 7 (57%) patients with ADT-naïve disease and 1 of 3 (33%) patients with CR disease. The median duration of treatment response was 24 months. The overall clinical benefit, therefore, was noted in 5 of 10 (50%) patients. Therapy was well tolerated.
Conclusions: Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer. We used commercially available soy products. We also show that soy can provide benefit in CR prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer.
No standard therapeutic option exists for men with prostate cancer who have failed local therapy with radical prostatectomy (RP) and salvage radiotherapy (RT), have no gross metastatic disease, and whose only manifestation of disease is a rising prostate-specific antigen (PSA) level. The therapeutic options for such patients include observation, androgen-deprivation therapy (ADT), or clinical trial. The use of ADT in this scenario remains controversial because there is no proven survival benefit and treatment has potential morbidity, which may at a minimum impair the quality of life of these patients. A nontoxic, inexpensive, readily available, and effective approach to this situation would be welcomed by patients and their caregivers.
Soybeans and their components have been studied extensively in prostate cancer research. A diet that is rich in soy has the potential to decrease the incidence of prostate cancer, and soy may modulate the disease process for established cancers. In our clinical practice, we began to use commercially available soy milk as an alternative to observation in men with biochemical relapse of their prostate cancer. In addition, we have offered this therapy to select asymptomatic men with CR and low-volume disease as an initial treatment along with continued ADT in advance of the use of secondary hormonal manipulations and/or chemotherapy. We describe our experience in 10 men in clinical practice.
- Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605.
- Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.
- Pendleton JM, Tan WW, Anai S, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008;8:132.
- Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol2005;15:17–22.
- Zhang LL, Li L, Wu DP, et al. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin 2008;29:1060–1068.
- Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093–1100.
- Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991;30:133–140.
- Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553–557.
- Akiyama T, Ogawara H. Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Method Enzymol1991;201:362–370.
- Coward L, Barnes NC, Setchell KDR, et al. Genistein, daidzein, and their beta-glycoside conjugates-antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 1993;41:1961–1967.
- Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;22:335–345.
- Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog2007;6:3.
- Naik HR, Lehr JE, Pienta KJ. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res 1994;14:2617–2619.
- Ogawara H, Akiyama T, Watanabe S, et al. Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones. J Antibiot (Tokyo) 1989;42:340–343.
- Watanabe T, Shiraishi T, Sasaki H, et al. Inhibitors for protein-tyrosine kinases, ST638 and genistein: induce differentiation of mouse erythroleukemia cells in a synergistic manner. Exp Cell Res 1989;183:335–342.
- Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 2002;186:11–18.
- Niculescu MD, Pop EA, Fischer LM, et al. Dietary isoflavones differentially induce gene expression changes in lymphocytes from postmenopausal women who form equol as compared with those who do not. J Nutr Biochem2007;18:380–390.
- Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol2000;18:847–853.
- Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39–66.
- Lee D. High androgen receptor levels are predictive of decreased survival in prostate cancer. Clin Prostate Cancer2003;2:13–14.
- Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 2007;137:1769–1775.
- Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64:510–515.
- Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005;48:922–930.
- Kwan W, Duncan G, Van Patten C, et al. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer 2010;62:198–207.
- Kurahashi N, Iwasaki M, Sasazuki S, et al. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007;16:538–545.
- Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res2007;67:5033–5041.
- Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17 suppl 2:S72–S79.